Player FM 앱으로 오프라인으로 전환하세요!
Update from ASCO GI 2023 Ep 2: lower GI cancer highlights
Manage episode 354280042 series 3293376
COR2ED Medical Education: This episode, covers the highlights on colorectal cancer from ASCO GI 2023. Prof. Andrea Sartore-Bianchi (Niguada Cancer Center, Milan, Italy) and Prof. Shubham Pant (MD Anderson Cancer Center, Houston, TX, USA) discuss a number of key abstracts from the meeting and their implications for clinical practice.
The experts start by discussing the SUNLIGHT trial which studied the use of trifluridine/tipiracil plus bevacizumab as third-line treatment in refractory colorectal cancer. The discussion then moves on to a trial which evaluated the kinetics of post operative circulating cell-free DNA and its impact on minimal residual cell detection in patients with stage I-III colorectal cancer.
The third abstract the experts discussed was a phase I trial which study botensilimab plus balstilimab in MSS colorectal cancer patients. Finally they discuss the long term results of NRG-GI002, a phase 2 trial which looked at the use of total neoadjuvant therapy in locally advanced rectal cancer.
87 에피소드
Manage episode 354280042 series 3293376
COR2ED Medical Education: This episode, covers the highlights on colorectal cancer from ASCO GI 2023. Prof. Andrea Sartore-Bianchi (Niguada Cancer Center, Milan, Italy) and Prof. Shubham Pant (MD Anderson Cancer Center, Houston, TX, USA) discuss a number of key abstracts from the meeting and their implications for clinical practice.
The experts start by discussing the SUNLIGHT trial which studied the use of trifluridine/tipiracil plus bevacizumab as third-line treatment in refractory colorectal cancer. The discussion then moves on to a trial which evaluated the kinetics of post operative circulating cell-free DNA and its impact on minimal residual cell detection in patients with stage I-III colorectal cancer.
The third abstract the experts discussed was a phase I trial which study botensilimab plus balstilimab in MSS colorectal cancer patients. Finally they discuss the long term results of NRG-GI002, a phase 2 trial which looked at the use of total neoadjuvant therapy in locally advanced rectal cancer.
87 에피소드
Alle episoder
×플레이어 FM에 오신것을 환영합니다!
플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.